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Key points
 The short-chain fatty acids (SCFAs) are bacterial metabolites produced during the colonic
fermentation of undigested carbohydrates, such as dietary fibre and prebiotics, and canmediate
the interaction between the diet, the microbiota and the host.
 We quantified the fraction of colonic administered SCFAs that could be recovered in the
systemic circulation, the fraction that was excreted via the breath and urine, and the fraction
that was used as a precursor for glucose, cholesterol and fatty acids.
 This information is essential for understanding the molecular mechanisms by which SCFAs
beneficially affect physiological functions such as glucose and lipid metabolism and immune
function.
Abstract The short-chain fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial
metabolites that mediate the interaction between the diet, the microbiota and the host. In
the present study, the systemic availability of SCFAs and their incorporation into biologically
relevant molecules was quantified. Known amounts of 13C-labelled acetate, propionate and
butyrate were introduced in the colon of 12 healthy subjects using colon delivery capsules and
plasma levels of 13C-SCFAs 13C-glucose, 13C-cholesterol and 13C-fatty acids were measured. The
butyrate-producing capacity of the intestinal microbiota was also quantified. Systemic availability
of colonic-administered acetate, propionate and butyrate was 36%, 9% and 2%, respectively.
Conversion of acetate into butyrate (24%) was the most prevalent interconversion by the colonic
microbiota and was not related to the butyrate-producing capacity in the faecal samples. Less
than 1% of administered acetate was incorporated into cholesterol and <15% in fatty acids. On
average, 6%of colonic propionatewas incorporated into glucose. The SCFAsweremainly excreted
via the lungs after oxidation to 13CO2, whereas less than 0.05% of the SCFAs were excreted into
urine. These results will allow future evaluation and quantification of SCFA production from
13C-labelled fibres in the human colon by measurement of 13C-labelled SCFA concentrations in
blood.
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Abbreviations AUC, area under the curve; CDC, colonic delivery capsule;Cl, clearance;Css, steady state concentration;
cumPDR, cumulative percentage of administered dose; D, administered dose; DNL, de novo lipogenesis; FFAR, free
fatty acid receptor; GC-C-IRMS, gas chromatography combustion isotope ratio mass spectrometry; GC-MS, gas
chromatography-mass spectrometry; MCT, monocarboxylate transporter; OCTT, orocecal transit time; SA, systemic
availability; SCFA, Short-chain fatty acids; TCA, tricarboxylic acid; T20%, time of release of the CDC.
Introduction
The short-chain fatty acids (SFCAs), mainly comprising
acetate, propionate and butyrate, are produced in the
large intestine by microbial degradation of undigested
carbohydrates and, to a lesser extent, proteins. They
are increasingly recognized as signalling molecules that
mediate the interaction between the diet, the gut micro-
biota and the host. Locally in the gut, SCFAs are crucial
for intestinal health because they serve as the major
energy substrates for the colonocytes and also because of
their anti-inflammatory and anti-carcinogenic properties
(Hamer et al. 2008). In addition, they affect gut and
host metabolism by activating the G-protein coupled cell
surface receptorsGPR-41 andGPR-43 (Brown et al. 2003),
later renamed as free fatty acid receptors (FFAR)-3 and
FFAR-2, which are involved in the regulation of glucose
and lipidmetabolism (den Besten et al. 2013b). Activation
of those receptors on the enteroendocrine L-cells in
the colon results in the secretion of the gut-derived
satiety hormones glucagon-like peptide 1 and peptide
YY, providing a mechanism for the beneficial effect of
SCFAs on energy intake and satiety (Canfora et al. 2015).
Finally, a fraction of the colonic produced SCFAs reaches
the systemic circulation and directly affects the function
and metabolism of peripheral organs and tissues, such
as the liver, the pancreas, adipocytes, immune cells and
skeletal muscle tissue. As a consequence, SCFAs have been
involved inmaintaining glucose and lipidmetabolism and
may provide an important target for tackling disorders
that are associated with disturbances of glucose and lipid
metabolism, such as obesity, metabolic syndrome or type
2 diabetes.
To further understand how SCFAs provide a
mechanistic link between the diet, the microbiota and
health benefits, it is necessary to quantify the extent to
which fermentation-derived SCFAs reach the systemic
circulation. Quantitative information on the assimilation
of SCFAs into biologically relevant molecules in humans
may also contribute to unravelling the mechanism by
which SCFAs elicit systemic effects. Currently, SCFAs
are most often measured in faeces or in fasting blood
samples. However, because of the rapid absorption of
SCFAs by the colonocytes, only an estimated 5% of
produced SCFAs is excreted in faeces (McNeil et al.
1978), rendering faecal measurements unrepresentative
of colonic SCFA production. In addition, extensive
metabolism in colonocytes and the liver results in low
plasma levels of SCFAs.
In the present study, stable isotope technology
was applied to determine the systemic availability of
each SCFA after colonic administration of 13C-labelled
SCFAs. The systemic availability is the fraction of an
administered dose of unchanged substrate that reaches the
systemic circulation. In addition, the occurrence of inter-
conversions was evaluated and the incorporation of the
colonic-derived 13C-SCFAs into glucose, free fatty acids
and cholesterol was quantified. Stable isotope technology
is a very sensitive analytical technique that allows the
selective measurement in the plasma of those SCFAs that
originate from the colon.
Methods
Ethical approval
The study procedure was approved by the Ethics
Committee of Leuven University Hospital, Leuven,
Belgium. Written, informed consent was obtained from
all subjects and the study conformed to the Declaration
of Helsinki. The study was registered at: ClinicalTrials.gov
(NCT01757379).
Colonic delivery of SCFAs
Known amounts of the individual 13C-labelled SCFAs
(13C-acetate, 13C-propionate or 13C-butyrate) were
delivered into the colon of healthy subjects using colon
delivery capsules (CDCs). Hard gelatine capsules (size 0)
were filled with either 200 mg of 13C-labelled sodium
acetate ([1-13C]acetate), 170 mg of 13C-labelled sodium
propionate ([1-13C]propionate) or 495mg of 13C-labelled
sodium butyrate ([1-13C]butyrate) (Euriso-top, St Aubin,
Ce´dex, France) together with 9.0% (w/w) citric acid
(Sigma-Aldrich, Bornem, Belgium). The addition of citric
acid was necessary to keep the pH of the capsule contents
below pH 6.5 and to prevent dissolution of the coating
from the inside–out as a result of water intrusion into
the capsules. Before and after filling, the capsules were
weighed to determine their exact content. The capsules
were coated manually with a pH-dependent film made
up of Eudragit S100 (Evonik, Darmstadt, Germany) with
diethyl phthalate (Omega Pharma, Nazareth, Belgium)
(25%w/wwith respect to polymer) as plasticizer. Eudragit
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S100 only dissolves at a pH >7.0 (Chourasia et al. 2003).
The coating thickness was estimated from the increase in
weight after coating and expressed as mg cm–² capsule
surface. Coating thickness was varied between 13.5 and
23.3 mg cm–².
Similar capsules containing 5.2 mg (in acetate capsules)
or 4.0 mg (in propionate and butyrate capsules) of
methylene blue were prepared to assess the pH resistance
of the polymer coating. The release of methylene blue
from the coated capsules was monitored during in vitro
dissolution tests in sodium phosphate buffers (0.1 M) of
pH 6.3, 6.8, 7.0 and 7.2 according to the USP XXV paddle
method (150 rpm) at 37 °C. The concentration of the
marker was quantified colorimetrically at 664 nm. All
measurements were performed in duplicate.
Study design
Twelve healthy subjects (seven female and five males, aged
26± 6 years, bodymass index 22± 3 kgm–2) participated
in a randomized, cross-over study. Exclusion criteria were
previous abdominal surgery (except fromappendectomy),
history of chronic gastrointestinal conditions (e.g.
inflammatory bowel diseases, irritable bowel syndrome
and coeliac disease) or being on a low calorie or vegetarian
diet. Female subjects were excluded if they were pre-
gnant or lactating. All subjects were free of medication
influencing the gut transit or intestinal microbiota for
14 days and of antibiotics for 1 month. Intake of pre-
and probiotics was prohibited during the study period.
Subjects were also excluded if they had donated blood
during the last 3 months, suffered from low blood
haemoglobin levels or had participated in experiments
involving ionizing radiation during the last year. Each
subject performed three test days (one type of SCFA per
test day) with 1 week inbetween. During the 3 days prior
to a test day, the subjects consumed a low-fibre diet and
avoided alcohol intake.On the eveningprior to the test day,
a non-fermentable standard meal (lasagne) was offered
to avoid changes in colonic fermentation during the
different test days. On themorning of the test, the subjects
received two coated capsules containing either 13C-acetate,
13C-propionate or 13C-butyrate with a standard breakfast
(pancake; 250 kcal) labelled with inulin-14C-carboxylic
acid (74 kBq;AmericanRadiolabelledChemicals, St Louis,
MO, USA) as a marker for orocecal transit time (OCTT)
(Verbeke et al. 2005). During each test day, a primed
continuous I.V. infusion of deuterated SCFAs was applied
([2H3]-acetate: 10 μmol kg−1 + 20 μmol kg−1 h−1;
[2H5]-propionate: 1 μmol kg−1 + 2 μmol kg−1 h−1;
[2H7]-butyrate: 0.5 μmol kg−1 + 1 μmol kg−1 h−1) to
quantify the clearance of each SCFA. Before breakfast
and at regular time points during the day, breath, blood
and urine samples were collected. Breath samples were
collected every 20 min up to 10 h after breakfast. Blood
samples were collected every 1 h during the first 4 h, every
20 min from 4 to 9 h, and every 40 min from 9 h to
12 h. A basal urine sample and 0–4 h, 4–8 h, 8–12 h
and 12–24 h urine fractions were collected in recipients
containing neomycin to prevent bacterial growth. After
4 and8h, the subjects received a standardnon-fermentable
meal (white breadwith hamor cheese). Finally, all subjects
delivered a faecal sample that, within 10 h after collection,
was frozen at −80°C until analysis.
Analytical procedures
Analysis of breath samples. Measurements of 13CO2, H2
and 14CO2 in breath samples were performed as described
previously (Verbeke et al. 2005). The results for 13CO2
were expressed as cumulative percentages of administered
dose (cumPDR) (Braden et al. 2007). The time of release
from the capsules (T20%) was defined as the time at which
20% of the cumPDR was recovered in the breath. The
cumPDR values after 12 h were corrected for the 13CO2
that is produced via oxidation but is not excreted using
a correction factor of 0.55 as suggested by Maurer et al.
(2013). The OCTT was defined as the time at which a
significant increase in 14C from background was seen in
the breath (i.e. 2.5 times the SDof all previous points above
the running average of all previous points) (Verbeke et al.
2005).
Analysis of total SCFA concentrations in plasma and
urine samples. Total SCFA concentrations in plasma
were measured using gas chromatography (GC) after
purification and concentration of the samples with
hollow fibre supported liquid membrane extraction as
described by Zhao et al. (2007). To measure total SCFA
concentrations in urine, samples (3.0ml)were spikedwith
150μl of internal standardmix (83mg l−1 2-ethyl-butyric
acid and 200 mg l−1 3-methyl-valeric acid) and 500 μl
of 1.0 M sodium hydroxide and concentrated to dryness.
After the addition of 200 μl of 37.0% HCl to the residue,
SCFAs were extracted in 1.0 ml of diethyl ether. The ether
extracts were injected (0.5 μl) in pulsed splitless mode
into the injector at 200°C. Chromatographic analysis was
carried out on a fused-silica capillary column with Free
Fatty Acid Phase (DB-FFAP 125-3237; J&W Scientific,
Agilent Technologies, Santa Clara, California, USA) of
30m× 0.53mm inner diameter coated with 0.50μmfilm
thickness using an Agilent 6890 N GC system equipped
with a flame ionization detector (Agilent Technologies).
Column temperature was started at 100°C (3 min) and
increased to 140°C (5min) at a rate of 4°Cmin–1 followed
by an increase to 235°C (5 min) at a rate of 40°C min–1.
Helium was used as carrier gas in a constant flow mode
of 4.2 ml min−1 and the detector temperature was set
at 240°C. The flow rates of the detector gases hydro-
gen, air and nitrogen as make-up gas were 30, 300 and
C© 2016 The Authors. The Journal of Physiology C© 2016 The Physiological Society
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20 ml min−1, respectively. Data handling was carried
out with HP ChemStation Plus software (B.04.03; Agilent
Technologies).
Analysis of 13C- and 2H-enrichments of SCFAs in plasma
and urine samples. Plasma samples were deproteinized
and extracted according to Morrison et al. (2004),
whereas urine samples were only dried and extracted.
The extracted samples for analysis of 13C-enrichment
of SCFAs were injected (4 μl) in splitless mode at
240°C into a Delta-XP isotope ratio mass spectrometer
(Thermo Fisher Scientific, Bremen, Germany) equipped
with a Trace gas chromatograph and a combustion inter-
face type 3 (GC-C-IRMS). An AT-Aquawax-DA column
(30 m × 0.53 mm inner diameter and 1.00 μm film
thickness; Grace, Lokeren, Belgium) was used. The initial
oven temperature was 80°C (3 min) and ramped to
140°C at a rate of 4°C min–1 followed by an increase
to 240°C (10 min) at a rate of 16°C min–1. Helium
was used as carrier gas in a constant flow mode of
2.5 ml min−1. After elution from the GC column, the
compounds were oxidized into CO2 in the combustion
reactor after which the enrichment was measured in
the IRMS detector. To calculate the enrichment of
the SCFAs from the measured 13CO2 enrichment, the
number of labelled carbon atoms per molecule and the
enrichment of the administered substrate (13C-SCFAs)
were taken into account. Data were processed using
Isodat NT, version 2.0 (FinniganTM; Thermo Fisher
Scientific).
For the analysis of the 2H-enrichments of SCFAs, 1 μl
of the extracted samples was injected at 240°C in splitless
mode into the injector of a gas chromatograph equipped
with a quadrupole system (Trace GC Ultra and DSQ
II; Thermo Electron Corporation, Waltham, MA, USA)
with an AT-Aquawax DA column (30 m × 0.25 mm
inner diameter and 0.25 μm film thickness; Grace). The
initial oven temperature was 40°C (3 min) and ramped to
140°C at a rate of 4°C min–1 followed by an increase to
240°C (6 min) at a rate of 16°C min–1. Helium was used
as carrier gas in a constant flow mode of 1 ml min−1.
The transfer line was maintained at 240°C. The mass
spectrometer was operated in full scan monitoring mode
(m/z 33–650) and the source temperaturewas set at 250°C.
XcaliburTM software (Thermo Fisher Scientific) was
used for the automatization of the gas chromatography-
mass spectrometry (GC-MS) system and for data
acquisition.
Analysis of 13C-glucose. Total plasma glucose
concentrations and 13C-glucose enrichments were
measured using GC-C-IRMS after derivatization of
glucose to its aldonitrile penta acetate derivative
according to Schierbeek et al. (2009). The derivatized
samples were injected (1 μl) in splitless mode into the
GC-C-IRMS instrument equipped with an AT-5 ms
capillary column (30 m × 0.32 mm inner diameter and
1.0 μm film thickness; Grace). The injector temperature
was set at 250°C and the initial oven temperature
amounted to 95°C (30 s) and was increased to 300°C
(15 min) at 20°C min–1. The helium carrier flowed at a
constant rate of 1.5mlmin−1. To calculate the enrichment
of 13C-glucose from the measured enrichment of 13CO2,
it was assumed that one propionate molecule was
incorporated per glucose molecule.
Analysis of 13C-free fatty acids. The concentrations and
13C-enrichment in plasma of palmitic (C16:0), stearic
(C18:0) and oleic (C18:1, n-9) acid were measured using
GC-C-IRMS after prior conversion of the fatty acids into
their corresponding methyl esters as described by Wang
et al. (2012). Samples were injected (1 μl) at 250°C
in a splitless mode into an AT-aquawax-DA column
(30 m × 0.53 mm inner diameter and 1.0 μm film
thickness; Grace). The initial oven temperature was 50°C
(2 min) and ramped to 200°C (10 min) at a rate of
10°C min–1 followed by an increase to 220°C (15 min)
at a rate of 10°C min–1. Helium was used as carrier gas
in a constant flow mode of 2.5 ml min−1. To calculate
the enrichment of 13C-fatty acids from the measured
enrichment of 13CO2, we assumed that one acetate
molecule was incorporated per fatty acid molecule.
Analysis of 13C-cholesterol. Plasma samples for 13C-
enrichment measurements of cholesterol were saponified
and extracted in sequence with hexane and diethyl ether
according to Paik et al. (2008). The supernatant layer was
silylated usingN,O-Bis(trimethylsilyl)trifluoroacetamide.
The 13C-enrichment of cholesterol in plasma samples was
measured using GC-C-IRMS analysis with an Rxi-5 ms
capillary column (30 m × 0.25 mm inner diameter
and 0.5 μm film thickness; Interscience, Breda, The
Netherlands). Samples were injected (1 μl) in splitless
mode at 250°C into the column. The initial oven
temperature was 240°C (1 min) and was increased to
300°C (15 min) at 20°C min–1. Helium gas was used as
carrier gas and flowed at a constant rate of 2.5 ml min−1.
To calculate the enrichment of 13C-cholesterol from the
measured enrichment of 13CO2, it was assumed that
one acetate or propionate molecule was incorporated
per cholesterol molecule. Total cholesterol concentrations
were determined using standard laboratory techniques.
Analysis of butyrate-producing capacity in faecal samples.
Real-timePCRwas used to quantifyClostridium cluster IV,
Clostridium cluster XIV, butyryl-CoA:acetate-CoA trans-
ferase and butyrate kinase genes in faecal samples as
described previously (Boets et al. 2015).
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Calculations
Systemic availabilities of colonic acetate, propionate and
butyrate. The systemic availability of each SCFA was
determined by measuring 13C-acetate, 13C-propionate
and 13C-butyrate plasma concentrations up to 12 h
after colonic delivery of 13C-acetate, 13C-propionate
and 13C-butyrate, respectively, on three separate test
days. At each time point, total (labelled + unlabelled)
SCFA concentrations and 13C-SCFA enrichments were
measured. The plasma concentration of 13C-SCFAs
consists of the concentration of 13C-SCFAs naturally pre-
sent in the plasma and the concentration originating from
the colon. The concentration of 13C-SCFAs originating
from the colon at each time point (ncolon) was calculated
according to eqn (1) and allowed the construction of
13C-SCFA concentration vs. time graphs:
ncolon = ntot x AP tot − APplasma t0
APcolon − APplasma t0
(1)
where ntot is the total concentration of SCFAs
(labelled+ unlabelled);APtot is the 13C-enrichment of the
SCFAsmeasured in plasma at timepoint t;AP plasma t0 is the
13C-enrichment of the SCFAs measured in plasma at time
0; and APcolon is the 13C-enrichment of the administered
substrate.
To allow calculation of the clearance of the SCFAs,
a primed constant infusion with 2H-SCFAs was applied
during each test day. The 2H-enrichments of the SCFAs
were multiplied by the SCFA plasma concentrations to
calculate the 2H-SCFA concentrations. Subsequently, the
clearance (Cl; l h−1) was calculated from the 2H-SCFA
infusion rate (I2H-SCFA; μmol.h−1) and the steady state
2H-SCFA plasma concentration (Css; μmol l−1) was
obtained according to eqn (2):
Cl = I 2H−SCFA
CSS
(2)
13C-SCFA concentration vs. time graphs were used
to calculate the exposure to 13C-SCFAs in plasma using
the trapezoidal rule. Finally, knowing the administered
amount of each 13C-SCFA, the systemic availability
of 13C-acetate, 13C-propionate and 13C-butyrate was
calculated according to eqn (3):
SASCFA = AUC x ClSCFA
D capsule
× 100 (3)
where SA is the systemic availability (%); AUC is the area
under the curve of the 13C-SCFA concentration vs. time
graph (μmol h l−1); Cl is the clearance of the respective
SCFA (l h−1); and Dcapsule is the administered dose of the
respective SCFA (μmol).
Assimilation of SCFAs into biologically relevant
molecules. The fraction of colonic-derived propionate
used for glucose production was quantified from
the cumulative amount of 13C-glucose appearing in the
plasma after colonic administration of 13C-propionate
according to eqn (4).
F 13C−label recovered as glucose =
AUC x Clglucose
D13C−propionate
× 100 (4)
where F13C-label recovered as glucose is the the fraction of
administered 13C recovered in glucose (%); AUC is the
area under the curve of the 13C-glucose vs. time graph
(μmol h l−1); Clglucose is the clearance (l h−1) of glucose
that was calculated for each individual according to
Jani et al. (2008) and amounted to 8.9 ± 1.2 l h−1;
and D13C-propionate is the dose of colonic administered
13C-propionate (μmol).
Similarly, the fraction of 13C-acetate incorporated into
the most abundant fatty acids (palmitic, stearic and
oleic acid) was calculated according to eqn (4) using the
respective AUCs of the 13C-fatty acids vs. time graphs, the
clearance of palmitic, stearic and oleic acid, respectively,
and the administered dose of 13C-acetate. The clearance of
the fatty acids was obtained from literature and amounted
to 48, 30 and 45 l h−1 for palmitic, stearic and oleic acid,
respectively.
Finally, the extent to which intestinal acetate and
propionate were used for de novo synthesis of
cholesterol was determined. The fractional incorporation
of 13C-acetate and 13C-propionate into cholesterol was
calculated according to eqn (4) using the AUC of
the 13C-cholesterol vs. time graph, the clearance of
cholesterol and the administered dose of 13C-acetate and
13C-propionate, respectively. The clearance of cholesterol
was calculated for each individual based on body weight
and cholesterol levels as described by Turner et al. (2012)
and amounted to 0.15 ± 0.04 l h−1.
Statistical analysis
Statistical analyses were performed using SPSS, version
22.0 (IBM Corp, Armonk, NY, USA). All results are pre-
sented as the mean ± SD. Assumptions of normality were
checked with a Shapiro–Wilk test. The OCTT and time
of 13CO2 in breath samples were compared using a paired
samples t test. Bivariate correlations were performed with
Spearman’s rho. Significance was accepted at the 5% level.
Results
Delivery of SCFAs into the colon of healthy subjects
In vitro dissolution tests indicated an appropriate release
profile of the marker methylene blue from the CDCs
C© 2016 The Authors. The Journal of Physiology C© 2016 The Physiological Society
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(release after 45 min at pH 7.0) with a coating thickness
of 18.8 mg cm–² capsule surface (Fig. 1A).
To evaluate the in vivo performance of the capsules, the
time at which 13CO2, resulting from oxidation of released
13C-SCFAs, appearing in thebreathwas comparedwith the
OCTT, which was estimated from an increase of 14CO2 in
the breath (Verbeke et al. 2005). A simultaneous increase
in the breath of 13CO2 and 14CO2 indicates a correct release
of the CDCs content in the proximal colon (Fig. 1B).
No significant differences were observed between the
13CO2 excretion time (383 ± 105 min) and the OCTT
(399± 84min) in anyof the test days (P= 0.202) (Fig. 1C).
Systemic availabilities of colonic acetate, propionate
and butyrate
13C-SCFA concentration vs. time graphs were constructed
for the three test days of each subject and a representative
example is shown Fig. 2A. By calculating the area
under these 13C-SCFA concentrations vs. time graphs,
an exposure of 1.92 ± 1.13, 0.48 ± 0.26 and
0.21 ± 0.20 μmol h l−1 was obtained for 13C-acetate,
13C-propionate and 13C-butyrate, respectively. Total body
clearance of acetate, propionate and butyrate amounted
to 938 ± 287, 647 ± 176 and 1237 ± 592 l h−1,
respectively. On average, the fraction of colonic-derived
acetate, propionate and butyrate appearing in plasma
amounted to 36 ± 21%, 9.2 ± 5.9% and 2.4 ± 1.9%,
respectively (Fig. 2B).
SCFAs are interconverted by gut microbiota
The individual 13C-SCFAs were administered on separate
days to allow evaluation of the extent of interconversion
between the three SCFAs. After the administration
of 13C-acetate, the extent of its conversion into
13C-propionate and 13C-butyrate was determined by
quantifying the appearance of 13C-propionate and
13C-butyrate in plasma. Interconversion was quantified
in similar ways after the administration of 13C-propionate
and 13C-butyrate. The incorporation of 13C-acetate into
butyrate (Fig. 3A) was quantitatively the most significant
interconversion but all interconversions were detected. To
confirm that conversion of acetate into butyrate was a
result of bacterialmetabolismandnothumanmetabolism,
uncoated 13C-acetate capsules were administered. Because
these released 13C-acetate already in the proximal gastro-
intestinal tract, 13C-acetate was absorbed before it had
been in contact with bacteria and appeared in plasma
already after 120 min. No 13C-butyrate in plasma was
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Figure 1. In vitro and in vivo evaluation of the performance of the colon delivery capsules
A, in vitro dissolution profile of colon delivery capsules at different pH (n = 2). B, 14CO2 and 13CO2 appearance in
breath after administration of 13C-acetate, 13C-propionate and 13C-butyrate colon delivery capsules in 12 subjects.
The simultaneous rise in the breath of 14CO2 and 13CO2 indicates a correct delivery of 13C-acetate in the colon.
C, comparison of the time of release of the 13C-SCFAs from the capsules (indicated by the time point at which
20% of the cumulative amount recovered was obtained, t20%) and arrival of the test meal in the colon (indicated
by the orocecal transit time, OCTT); n = 36, except for OCTT (n = 30). Results are expressed as the mean ± SD.
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observed, confirming that contactwith bacteria is essential
for the interconversion to occur (Fig. 3B and C).
Quantification of the butyrate-producing capacity
of the intestinal microbiota
To relate the interconversion of acetate into butyrate to
the intestinal microbiota composition of the subjects,
the butyrate-producing capacity in a faecal sample was
quantified. RT-PCR was used to quantify genes coding for
butyrate kinase and butyryl-CoA:acetate CoA-transferase,
which are the dominant terminal enzymes in the
production of butyrate (Louis & Flint, 2007; Vital et al.
2013). In addition, the most abundant clusters of butyrate
producing bacteria (i.e. Clostridium clusters IV and XIVa)
were quantified (Fig. 4A). However, the extent of acetate
into butyrate conversion was not significantly related to
any of these parameters of butyrate-producing capacity
(Fig. 4B–E).
Utilization of colonic-derived propionate
in gluconeogenesis
Plasma 13C-glucose concentrations increased
simultaneously with 13C-propionate concentrations
(Fig. 5A). The cumulative amount of 13C-glucose was
23 ± 20.5 μmol h l−1. We calculated that 5.9 ± 4.7%
of the colonic administered propionate was used for
gluconeogenesis (Fig. 5B).
Incorporation of acetate into fatty acids
The 13C-enrichment and total concentrations of the most
abundant plasma fatty acids, palmitic acid (C16:0), stearic
acid (C18:0) and oleic acid (C18:1, n-9), were quantified
after 13C-acetate administration. Enrichment was mainly
observed in palmitic acid and, to a lesser extent, in stearic
and oleic acid (Fig. 5C). Up to 12.0 ± 8.7%, 1.0 ± 0.9%
and 1.0 ± 1.0% of administered acetate was assimilated
into palmitic, stearic and oleic acid, respectively (Fig. 5D).
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Incorporation of colonic-derived acetate
and propionate into cholesterol
After administration of 13C-acetate, 13C-cholesterol
readily appeared in plasma, whereas 13C-cholesterol was
hardly detectable after administration of 13C-propionate
(Fig. 5E). Only 0.101 ± 0.076% and 0.007 ± 0.005%
of administered 13C-acetate and 13C-propionate were
assimilated into cholesterol, respectively (Fig. 5F).
Conversion of SCFAs into carbon dioxide
The extent to which 13C-substrates are converted to 13CO2
at the whole-body level is most often estimated from
the excretion of 13CO2 in the breath. After 12 h, the
cumulative percentage of 13C-label recovered as 13CO2
in the breath after administration of 13C-propionate
amounted to47±13%,whereas 33±10%of administered
13C-acetate and18± 3%of administered 13C-butyratewas
recovered (Fig. 6). Application of the correction factor for
the 13CO2 that is retained in the body indicated that up
to 86 ± 24% of administered 13C-propionate, 60 ± 18%
of administered 13C-acetate and 33 ± 6% of administered
13C-butyrate was oxidized into 13CO2 within 12 h.
Urinary excretion
Subjects collected urine for 24 h in different fractions
(0–4 h, 4–8 h, 8–12 h, 12–24 h) to allow quantification
of the urinary excretion of 13C-SCFAs. After 24 h, only
up to 0.031 ± 0.020% of 13C-acetate, 0.008 ± 0.002%
of 13C-propionate and 0.0006 ± 0.0003% of 13C-butyrate
were retrieved in urine.
Discussion
By applying a direct, stable isotope based approach,
the present study provides quantitative information on
the uptake and elimination of SCFAs in different body
compartments and their assimilation into biologically
relevant molecules in humans. This information may
contribute to deciphering the mechanistic link between
fibre consumption and its health benefits.
Colonic delivery of SCFAs
The targeting of orally administered compounds to
the colon can be achieved using various strategies
including the use of coatings with a pH-sensitive
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A, gene copy numbers of butyrate-producing colon bacteria and butyrate-producing colon enzymes in faecal
samples (n = 11). B–C, correlation between acetate into butyrate conversion and enzymes involved in butyrate
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polymer, formulation of time-released systems, use of
carriers that are specifically degraded by colonic bacteria,
covalent linkage of the compound with a carrier,
bioadhesive systems and osmotic controlled drug delivery
systems (Charousia et al. 2003). These formulations have
been mainly developed to target drugs to the colon
not only for the treatment of local diseases such as
Crohn’s disease or ulcerative colitis, but also because of
the potential to deliver therapeutic peptides or proteins.
As a result of the absence of peptidases in the colon,
the peptide drug might be absorbed unchanged after
peroral administration. Targeted delivery of SCFAs to
the colon has previously been achieved using carriers
such as starch (Annison et al. 2003) or inulin (Chambers
et al. 2015). Upon arrival in the colon, the carriers are
fermented by the resident bacteria and release the SCFAs
that are attached to them. We preferred to use gelatine
capsules with a pH-dependent coating as a convenient
0.20
0.15
0.10
0.05
0.00
200 400
time (min)
time (min)
time (min)
600 8000
4
3
2
1
0
13
C
-p
ro
pi
on
at
e 
co
nc
en
tr
at
io
ns
 (
μM
)
13
C
-a
ce
ta
te
 c
on
ce
nt
ra
tio
n 
(μ
M
)
13
C
-S
C
FA
 c
on
ce
nt
ra
tio
n 
(n
M
)
13C
-glucose concentrations (μM
)
13C
-fatty acids concentration (μM
)
13C
-cholesterol concentration (μM
)
Fr
ac
tio
n 
13
C
 o
f a
ce
ta
te
re
co
ve
re
d 
in
 fa
tty
 a
ci
ds
 (
%
)
Fr
ac
tio
n 
13
C
 r
ec
ov
er
ed
in
 g
lu
co
se
 (
%
)
Fr
ac
tio
n 
13
C
 r
ec
ov
er
ed
 in
 c
ho
le
st
er
ol
 (
%
)
13C-propionate
13C-acetate 13C-propionate
13C-cholesterol
13C-acetate
13C-acetate
13C-palmitate
13C-stearate
13C-oleate
13C-cholesterol
13C-propionate
13C-glucose
A B
DC
0.25
0.20
0.15
0.10
0.05
0.00
0 200 400 600 800
2.5
2.0
1.5
1.0
0.5
0.0
300
0.5
0.4
0.3
0.2
0.1
0.0
0.4
0.3
0.2
0.1
0.0
25
20
15
10
5
0
20
15
10
5
0
C16 C18 C18:1
E F
200
100
0
20
15
10
5
0
0 200 400 600 800
25
20
15
10
5
0
Figure 5. Assimilation of 13C-SCFAs in biologically relevant molecules
A, typical example that shows the appearance of 13C-propionate followed by 13C-glucose in plasma after colonic
administration of 13C-propionate. B, fraction of administered 13C-propionate recovered in glucose (n = 12).
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vehicle to deliver well known amounts of SCFAs to
the colon.
Systemic availability of SCFAs
Estimates of the extraction of the SCFAs during passage
through the splanchnic bed have been reported and
are based either on differences in SCFA concentrations
in peripheral blood compared to their concentrations
in portal blood obtained during abdominal surgery
(Peters et al. 1992; Bloemen et al. 2009) or on isotope
dilution experiments (Pouteau et al. 1996). Estimates
for splanchnic extraction of acetate vary from 40% to
75% (Pouteau et al. 1996; Vogt et al. 2004), whereas an
extraction value of 90% for propionate has been reported
(Vogt et al. 2004). Because butyrate is the preferred
energy source for colonocytes, the majority of absorbed
butyratemay already be consumed by the colonicmucosa.
According to Cook and Sellin (1998), 70–90% of butyrate
is metabolized in the colonocytes (Cook & Sellin, 1998).
Bloemen et al. (2009) showed that the release of butyrate
from the liver is not significantly different from zero,
suggesting a splanchnic extraction of almost 100%. Of
note, all studies mention a wide interindividual variation
in SCFA levels, in both peripheral and portal blood (Peters
et al. 1992; Bloemen et al. 2009).
We combined colonic administration of 13C-labelled
SCFAs with I.V. administration of 2H-labelled SCFAs
to determine the SCFA systemic availability, assuming
a similar behaviour of both types of labelled SCFAs.
Although simultaneous infusion of 13C-acetate and
2H-acetate in the gut of pigs resulted in higher 13C-acetate
than 2H-acetate enrichment in plasma, suggesting in
vivo isotope exchange of the deuterium hydrogen atoms
in acetate and thus underestimation of the deuterium
enrichment (Kien et al. 1996), we did not find evidence
for such isotope exchange in the present study. Indeed,
the ion masses used to quantify acetate and 2H3-acetate
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Figure 6. Recovery of 13C-acetate, 13C-propionate and
13C-butyrate in the breath as 13CO2
Results are expressed as the mean ± SD (n = 12).
were m/z 60 and 63, respectively, with no quantifiable
ions at mass m/z 61, nor 62. Similarly, we did not find
evidence for isotope exchange of 2H7-butyrate, which was
quantified using a fragment ion with m/z of 63, rather
than the parent ion. Therefore, even if isotope exchange
occurred in the remaining part of the molecule, which
we cannot exclude, this will not have affected our results.
2H5-propionate was quantified using the parent ion at
m/z 79. Although smaller peaks at m/z 78 and 77 were
visible suggesting isotope exchange, the same ratios were
observed in the infusion solution as in the plasma samples,
indicating that the exchange probably occurred in the ion
source of the mass spectrometer rather than in vivo.
The values for systemic availability of acetate (36%)
and propionate (9%) obtained in the present study
correspond to a splanchnic extraction of 64% and 91%,
respectively, which is in good agreement with the reported
values. Also in the present study, a large interindividual
variation was observed. In addition, the direct stable iso-
tope approach enabled the detection of 13C-butyrate in
the plasma after colonic administration of 13C-butyrate
and the quantification of its systemic availability (2%) or
splanchnic extraction (98%).
Metabolism of SCFAs
Within 12 h after colonic administration, the vastmajority
of propionate (86%) was converted into CO2 of which
47% was recovered in the breath. The remainder was
retained in the body bicarbonate pool. Except from being
a substrate for gluconeogenesis, no other pathways for
the incorporation of propionate into other metabolites
are known and the fate of propionate appears to be a
rapid and almost complete conversion into CO2, which
probably proceeds in the liver. These results do not
allow differentiation between the fraction of propionate
that is directly converted into CO2 and that used for
gluconeogenesis followed by oxidation of the resulting
glucose into CO2. After administration of 13C-acetate,
recovery in the breath was lower compared to that of
13C-propionate. This may be because the labelled C does
not appear as 13CO2 but instead is exchanged in other
metabolites. These are the most probable metabolites
of the tricarboxylic acid (TCA) cycle (van Hall, 1999)
because acetate enters the TCA cycle after conversion
into acetyl-CoA. This exchange is only temporary because
the resulting metabolites re-enter the oxidative pathways
at a later time. This also explains the observation that
breath 13CO2 recoveries after I.V. 13C-acetate infusion
increase with the duration of the infusion and only
reach a plateau after 12 h of infusion (Mittendorfer
et al. 1998). Breath 13CO2 recoveries after colonic
administration of 13C-acetate have not been reported
in the literature. Reported 13CO2 recoveries after I.V.
13C-acetate administration vary from 40% to 81% (Wolfe
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& Jahoor, 1990; Pouteau et al. 1996; Mittendorfer et al.
1998).
The low recovery of 13CO2 after administration of
13C-butyrate (33%) is probably partly a result of the
exchange of the label into TCA metabolites. After
absorption in the colonocytes, butyrate is taken up in
the mitochondria of the cells where it undergoes the
β-oxidation pathway, which involves a series of five
enzymes, to form acetyl-CoA that subsequently enters the
TCA cycle (De Preter et al. 2012). A few other studies
that have compared the rate of colonic butyrate oxidation
in patients with ulcerative colitis and healthy controls
report on 13/14CO2 recoveries in the breath after colonic
administration of 13C- or 14C-labelled butyrate. Six hours
after rectal instillation of 14C-butyrate enemas, 52.9%
(range 44.4–61.5) of administered label was retrieved in
the breath (Den Hond et al. 1998). In another study, one
quarter of rectally instilled 13C-butyrate was recovered as
13CO2 after 4 h (Simpson et al. 2000). After I.V. infusion of
13C-butyrate in five healthy subjects, the 6 h cumulative
excretion of 13CO2 amounted to 49.9 ± 2.2% (Den
Hond et al. 1998). For all 13C-SCFAs, higher fractions of
administered dose are excreted in the breath as 13CO2 than
appear in the plasma, indicating that they are metabolized
prior to arrival in the systemic circulation (i.e. presumably
in the colonocytes and liver).
In the human kidney, monocarboxylate transporters
(MCTs) are responsible for the reabsorption of SCFAs and
ketone bodies (Halestrap & Meredith, 2004). Although
lactate is quantitatively the most important substrate for
these transporters, they have also been shown to reabsorb
SCFAs. As a consequence, urinary excretion of SCFAs is
low. After continuous infusion of sodium butyrate for 10
days in patients with acute leukaemia, only 0.21 ± 0.04‰
of the administered dose was retrieved in urine (Miller
et al. 1987). In healthy subjects, urinary levels of SCFAs
have been reported in the range 0.8–130 μM for acetate
and below 3 μM for propionate and butyrate (Perry et al.
1970).
In vivo cross-feeding
Cross-feeding involves the supply of breakdown products
of carbohydrates after partial hydrolysis by primary
degraders as secondary substrates to other bacteria (De
Vuyst & Leroy, 2011). In particular, acetate is known
to function as an intermediate in cross-feeding inter-
actions between colon bacteria, and plays a key role
in colonic butyrate production (Morrison et al. 2006;
Riviere et al. 2015). Morrison et al. (2006) incubated
human faecal slurries in vitro with 2H-labelled SCFAs and
quantified the interconversion between the SCFAs. After
6 h, 0.28 mol mol–1 labelled acetate was incorporated into
butyrate. In the present study, conversion of 13C-acetate
into 13C-butyrate was estimated to be 24%. Although
the contact time of 13C-acetate with the intestinal micro-
biota was shorter in vivo than in vitro because 13C-acetate
was rapidly absorbed into the plasma after release from
the CDCs, the value is only slightly lower than the
data of Morrison et al. (2006), suggesting that this
interconversion proceeds quite rapidly. Although no
evidence for incorporation of 2H-acetate into propionate
or 2H-propionate into butyrate was found in the in vitro
study, all possible interconversions could be detected,
although this was to a lower extent than the acetate into
butyrate interconversion. This discrepancy is probably
a result of the different analytical techniques used in
both studies. Morrison et al. (2006) applied GC-MS
analysis, which allowed differentiation between different
isotopomers of the SCFAs, although this is a less sensitive
technique than the isotope ratio mass spectrometry
applied in the present study. In a recent study in mice,
enrichments of cecal SCFAs were quantified after 6 h of
cecal infusion of 13C-labelled SCFA.Ahigh conversionwas
observed from acetate into butyrate, whereas there was a
low conversion from butyrate into acetate and between
butyrate and propionate, and very little interconversion
between acetate and propionate (den Besten et al. 2013a).
Propionate as a substrate for gluconeogenesis
Studies in lactating cows report that up to 61% of
glucose in blood is derived from gluconeogenesis with
propionate as the substrate (Wiltrout & Satter, 1972).
In sheep, corresponding values between 42% and 59%
have been reported (Leng et al. 1967). On the other
hand, up to 32% of colonic-derived propionate is
incorporated into glucose in sheep and up to 62%
in mice (Leng et al. 1967; den Besten et al. 2013a).
Compared to those values, the extent of incorporation
of colonic-derived propionate into glucose (5.9%) is
limited in humans, as shown by the results of the
present study. Indeed, propionate is the major sub-
strate for gluconeogenesis in ruminants (Bergman, 1990)
whereas, in humans, lactate and pyruvate are the major
gluconeogenic substrates with minor contributions of
alanine and glycerol (Garber et al. 1974). Several methods
based on stable isotope technology have quantified
in vivo the contribution of gluconeogenesis to the glucose
production in humans (Previs & Brunengraber, 1998).
However, the contributions of all gluconeogenic substrates
are included in these estimates and no human data on
the contribution of propionate to gluconeogenesis are
available.
More recently, in rats, it has been shown that propionate
is incorporated into glucose at the level of the intestine
(De Vadder et al. 2014). The resulting glucose is sensed
in the walls of the portal vein and induces a nervous
signal to the brain that influences food intake and glucose
homeostasis. These results may provide amechanistic role
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for propionate in the beneficial effects of dietary fibre.
Unfortunately, because of an inability to obtain portal
blood from healthy subjects, our results do not allow
determination of whether the observed incorporation of
13C-propionate into glucose occurs in the intestine or in
the liver.
Incorporation of acetate into fatty acids
Indirect methods to estimate de novo lipogenesis such as
indirect whole-body calorimetry, as well as directmethods
such as 2H2O infusion and mass isotopomer distribution
analysis, confirmed that de novo lipogenesis (DNL) is a
quantitatively minor pathway under normal conditions
of typical high-fat diets (Bjorntorp and Sjostrom, 1978;
Hellerstein et al. 1991; Hellerstein et al. 1996). Absolute
DNL was estimated at less than 1 g being synthesized
per day, which is low compared to a dietary fat intake
of typically 100 g day–1 (Hellerstein et al. 1996). Studies
using mass isotopomer distribution analysis I.V. infuse
13C-acetate to enrich the acetyl-CoA-precursor pool
and express the fractional hepatic DNL as fraction of
newly synthesized lipid compared to the lipid already
present and not as fraction of administered acetate
incorporated in the lipid. As a consequence, it is not
possible to compare the results obtained in the present
studywith the results reported in literature. Almost 15%of
colonic-administered acetate was incorporated into fatty
acids in the present study. However, this only corresponds
to an absolute amount of 0.229 ± 0.175 g of newly
synthesized fatty acids, which is still far below the 1 g
threshold. It needs to be taken into account that only
5 mmol of 13C-labelled acetate was administered in the
colon delivery capsules, whereas the amount of acetate
produced in the colon on a western diet (20 g of dietary
fibre) has been estimated at150 mmol per day (Wolever
et al. 1995).
Incorporation of acetate and propionate into
cholesterol
It has been calculated that the rate of de novo synthesis
of cholesterol amounts to 10 ± 6 mg kg−1 day−1
in healthy adults (Renfurm et al. 2004). Because the
biosynthesis of cholesterol starts from the two-carbon
acetate group of acetyl-CoA, it has been suggested that
dietary fibres that are fermented into a high proportion of
acetate might increase serum cholesterol levels. However,
unlike propionate and butyrate, the majority of plasma
acetate originates from endogenous metabolism and the
contribution of colonic-derived acetate to cholesterol
synthesis may be less important. Indeed, the present study
showed that less than0.1%of colonic-administeredacetate
was incorporated into cholesterol. This value is of the
same order of magnitude as the value of 0.7% reported
by Hellman et al. (1954) after oral administration of
14C-acetate. Inmice, the fractional synthesis of cholesterol
from acetate was 0.7 ± 0.1% (den Besten et al. 2013a).
Propionate did not contribute to cholesterol synthesis,
neither in the present study, nor in the study in mice by
den Besten et al. (2013a).
Limitations of the present study
For calculation of the systemic availability, it was assumed
that the absorption of the 13C-SCFAs from the colonic
lumen was quantitative. The major part of SCFAs
is transported in dissociated form across the apical
membrane of the colonocytes by MCT-1, the electro-
genic sodium-dependent MCT-1 or an SCFA-HCO3−
exchanger of unknown identity (den Besten et al. 2013). It
is generally assumed that the colon has a large capacity to
absorb SCFAs, with estimates of 6.1–12.6 μmol cm–² h–1
(He et al. 2006). Because the human colon has a mucosal
surface area of20 000 cm² (Helander & Fandriks, 2014),
up to 120–250mmolof SCFAs couldbe absorbed every 1h.
To confirm a quantitative SCFA absorption, a complete
stool collection for 3–5 days after each test day would
have been required for quantifying residual 13C-SCFAs.
This would have placed an additional burden on the
protocol, which was already onerous for the participants,
and therefore this was not performed. Only one stool
sample was collected for the analysis of the microbial
butyrate-producing capacity.
In the present study, the metabolic fate of the SCFAs
was evaluated in standardized feeding conditions (i.e. after
administration of a non-fermentable standard breakfast
and lunch). Whether the oxidation and/or incorporation
of SCFAs in biomolecules differs in fasting conditions
remains to be investigated.
Conclusions
The set-up and methodology used in the present study
allowed quantification of the percentages of acetate,
propionate and butyrate originating from the colon
that reached the systemic circulation. In addition, the
metabolism and assimilation of acetate, propionate
and butyrate into biologically relevant molecules were
measured.
In the future, these results will allow the evaluation
and quantification of SCFA production from varying
13C-labelled fibres in the human colon by measurement
of 13C-labelled SCFA concentrations in the blood and
multiplication of the amounts of SCFAs that reached the
plasma with the systemic availability index calculated in
the present study. In addition, the availability of plasma
clearance values for each SCFA will allow calculation of
fluxes under different conditions when combined with
plasma SCFA measurements.
C© 2016 The Authors. The Journal of Physiology C© 2016 The Physiological Society
J Physiol 595.2 Short-chain fatty acid systemic availability and metabolism in humans 553
References
Annison G, Illman RJ & Topping DL (2003). Acetylated,
propionylated or butyrylated starches raise large bowel
short-chain fatty acids preferentially when fed to rats. J Nutr
133, 3523–3528.
Bergman EN (1990). Energy contributions of volatile fatty
acids from the gastrointestinal tract in various species.
Physiol Rev 70, 567–590.
Bjorntorp P & Sjostrom L (1978). Carbohydrate storage in
man: speculations and some quantitative considerations.
Metab Clin Exp 27, 1853–1865.
Bloemen JG, Venema K, van de Poll MC, Olde Damink SW,
Buurman WA & Dejong CH (2009). Short chain fatty acids
exchange across the gut and liver in humans measured at
surgery. Clin Nutr 28, 657–661.
Boets E, Deroover L, Houben E, Vermeulen K, Gomand SV,
Delcour JA & Verbeke K (2015). Quantification of in vivo
colonic short chain fatty acid production from inulin.
Nutrients 7, 8916–8929.
Braden B, Lembcke B, Kuker W & Caspary WF (2007).
C-13-breath tests: Current state of the art and future
directions. Dig Liver Dis 39, 795–805.
Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L,
Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser
NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder
JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord
SM, Wise A & Dowell SJ (2003). The Orphan G
protein-coupled receptors GPR41 and GPR43 are activated
by propionate and other short chain carboxylic acids. J Biol
Chem 278, 11312–11319.
Canfora EE, Jocken JW & Blaak EE (2015). Short-chain fatty
acids in control of body weight and insulin sensitivity. Nat
Rev Endocrinol 11, 577–591.
Chambers ES, Viardot A, Psichas A, Morrison DJ,
Murphy KG, Zac-Varghese SE, MacDougall K, Preston T,
Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL,
Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS,
Bloom SR, Morley W, Clegg S & Frost G (2015). Effects
of targeted delivery of propionate to the human colon
on appetite regulation, body weight maintenance
and adiposity in overweight adults. Gut 64,
1744–1754.
Chourasia MK & Jain SK (2003). Pharmaceutical approaches to
colon targeted drug delivery systems. J Pharm Pharm Sci 6,
33–66.
Cook SI & Sellin JH (1998). Review article: short chain fatty
acids in health and disease. Aliment Pharmacol Ther 12,
499–507.
De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit
F, Rutgeerts P & Verbeke K (2012). Impaired butyrate
oxidation in ulcerative colitis is due to decreased butyrate
uptake and a defect in the oxidation pathway. Inflamm Bowel
Dis 18, 1127–1136.
De Vadder F, Kovatcheva-Datchary P, Goncalves D,
Vinera J, Zitoun C, Duchampt A, Backhed F & Mithieux G
(2014). Microbiota-generated metabolites promote
metabolic benefits via gut-brain neural circuits. Cell 156,
84–96.
De Vuyst L & Leroy F (2011). Cross-feeding between
bifidobacteria and butyrate-producing colon bacteria
explains bifdobacterial competitiveness, butyrate
production, and gas production. Int J Food Microbiol 149,
73–80.
den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A,
van Eunen K, Muller M, Groen AK, Hooiveld GJ, Bakker BM
& Reijngoud DJ (2013a). Gut-derived short-chain fatty acids
are vividly assimilated into host carbohydrates and lipids.
Am J Physiol Gastrointest Liver Physiol 305, G900–G910.
den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud
DJ & Bakker BM (2013b). The role of short-chain fatty acids
in the interplay between diet, gut microbiota, and host
energy metabolism. J Lipid Res 54, 2325–2340.
Den Hond E, Hiele M, Evenepoel P, Peeters M, Ghoos Y &
Rutgeerts P (1998). In vivo butyrate metabolism and colonic
permeability in extensive ulcerative colitis. Gastroenterology
115, 584–590.
Garber AJ, Menzel PH, Boden G & Owen OE (1974). Hepatic
ketogenesis and gluconeogenesis in humans. J Clin Invest 54,
981–989.
Halestrap AP & Meredith D (2004). The SLC16 gene family-
from monocarboxylate transporters (MCTs) to aromatic
amino acid transporters and beyond. Pflugers Arch 447,
619–628.
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ &
Brummer RJ (2008). Review article: the role of butyrate on
colonic function. Aliment Pharmacol Ther 27, 104–119.
He T, Priebe MG, Harmsen HJ, Stellaard F, Sun X, Welling GW
& Vonk RJ (2006). Colonic fermentation may play a role in
lactose intolerance in humans. J Nutr 136, 58–63.
Helander HF & Fandriks L (2014). Surface area of the digestive
tract – revisited. Scand J Gastroenterol 49, 681–689.
Hellerstein MK, Christiansen M, Kaempfer S, Kletke C, Wu K,
Reid JS, Mulligan K, Hellerstein NS & Shackleton CH
(1991). Measurement of de novo hepatic lipogenesis in
humans using stable isotopes. J Clin Invest 87, 1841–1852.
Hellerstein MK, Schwarz JM & Neese RA (1996). Regulation of
hepatic de novo lipogenesis in humans. Annu Rev Nutr 16,
523–557.
Hellman L, Rosenfeld RS & Gallagher TF (1954). Cholesterol
synthesis from C14-acetate in man. J Clin Invest 33, 142–149.
Jani R, Molina M, Matsuda M, Balas B, Chavez A, DeFronzo
RA & Abdul-Ghani M (2008). Decreased non-insulin-
dependent glucose clearance contributes to the rise in fasting
plasma glucose in the nondiabetic range. Diabetes care 31,
311–315.
Kien CL, Murray RD, Ailabouni A, Powers P, Kepner J, Powers
L & Brunengraber H (1996). Stable isotope model for
assessing production of short chain fatty acids from colon-
derived sugar: application in pigs. J Nutr 126, 3069–3076.
Leng RA, Steel JW & Luick JR (1967). Contribution of
propionate to glucose synthesis in sheep. Biochem J 103,
785–790.
Louis P & Flint HJ (2007). Development of a semiquantitative
degenerate real-time PCR-based assay for estimation of
numbers of butyryl-coenzyme A (CoA) CoA transferase
genes in complex bacterial samples. Appl Environ Microbiol
73, 2009–2012.
C© 2016 The Authors. The Journal of Physiology C© 2016 The Physiological Society
554 E. Boets and others J Physiol 595.2
Maurer MJ, Schellekens RC, Wutzke KD & Stellaard F (2013).
Isotope-labelled urea to test colon drug delivery devices in
vivo: principles, calculations and interpretations. Isotopes
Environ Health Stud 49, 473–491.
McNeil NI, Cummings JH & James WP (1978). Short chain
fatty acid absorption by the human large intestine. Gut 19,
819–822.
Miller AA, Kurschel E, Osieka R & Schmidt CG (1987). Clinical
pharmacology of sodium butyrate in patients with acute
leukemia. Eur J Cancer Clin Oncol 23, 1283–1287.
Mittendorfer B, Sidossis LS, Walser E, Chinkes DL &
Wolfe RR (1998). Regional acetate kinetics and oxidation in
human volunteers. Am J Physiol Endocrinol Metab 274,
E978–E983.
Morrison DJ, Cooper K, Waldron S, Slater C, Weaver LT &
Preston T (2004). A streamlined approach to the analysis of
volatile fatty acids and its application to the measurement of
whole-body flux. Rapid Commun Mass Spectrom 18,
2593–2600.
Morrison DJ, Mackay WG, Edwards CA, Preston T, Dodson B
&Weaver LT (2006). Butyrate production from oligofructose
fermentation by the human faecal flora: what is the
contribution of extracellular acetate and lactate? Br J Nutr
96, 570–577.
Paik MJ, Yu J, Hu MB, Kim SJ, Kim KR, Ahn YH, Choi S & Lee
G (2008). Gas chromatographic-mass spectrometric analyses
of cholesterol and its precursors in rat plasma as
tert-butyldimethylsilyl derivatives. Clin Chim Acta 396,
62–65.
Perry TL, Hansen S, Diamond S, Bullis B, Mok C &Melancon
SB (1970). Volatile fatty acids in normal human
physiological fluids. Clin Chim Acta 29, 369–374.
Peters SG, Pomare EW & Fisher CA (1992). Portal and
peripheral blood short chain fatty acid concentrations
after caecal lactulose instillation at surgery. Gut 33,
1249–1252.
Pouteau E, Piloquet H, Maugeais P, Champ M, Dumon H,
Nguyen P & Krempf M (1996). Kinetic aspects of acetate
metabolism in healthy humans using [1-13C] acetate. Am J
Physiol Endocrinol Metab 271, E58–E64.
Previs SF & Brunengraber H (1998). Methods for measuring
gluconeogenesis in vivo. Curr Opin Clin Nutr Metab Care 1,
461–465.
Renfurm LN, Bandsma RHJ, Verkade HJ, Hulzebos CV, van
Dijk T, Boer T, Stellaard F, Kuipers F & Sauer PJJ (2004).
Cholesterol synthesis and de novo lipogenesis in premature
infants determined by mass isotopomer distribution
analysis. Pediatr Res 56, 602–607.
Riviere A, Gagnon M, Weckx S, Roy D & De Vuyst L (2015).
Mutual cross-feeding interactions between Bifidobacterium
longum subsp. longum NCC2705 and Eubacterium rectale
ATCC 33656 explain the bifidogenic and butyrogenic effects
of arabinoxylan oligosaccharides. Appl Environ Microbiol 81,
7767–7781.
Schierbeek H, Moerdijk-Poortvliet TC, van den Akker CH, te
Braake FW, Boschker HT & van Goudoever JB (2009).
Analysis of [U-13C6]glucose in human plasma using liquid
chromatography/isotope ratio mass spectrometry compared
with two other mass spectrometry techniques. Rapid
Commun Mass Spectrom 23, 3824–3830.
Simpson EJ, Chapman MA, Dawson J, Berry D, Macdonald IA
& Cole A (2000). In vivo measurement of colonic butyrate
metabolism in patients with quiescent ulcerative colitis. Gut
46, 73–77.
Turner S, Voogt J, Davidson M, Glass A, Killion S, Decaris J,
Mohammed H, Minehira K, Boban D, Murphy E,
Luchoomun J, Awada M, Neese R & Hellerstein M (2012).
Measurement of reverse cholesterol transport pathways in
humans: in vivo rates of free cholesterol efflux, esterification,
and excretion. J Am Heart Assoc 1, e001826.
van Hall G (1999). Correction factors for 13C-labelled
substrate oxidation at whole-body and muscle level. Proc
Nutr Soc 58, 979–986.
Verbeke K, de Preter V, Geboes K, Daems T, van den Mooter G,
Evenepoel P & Rutgeerts P (2005). In vivo evaluation of a
colonic delivery system using isotope techniques. Aliment
Pharmacol Ther 21, 187–194.
Vital M, Penton CR, Wang Q, Young VB, Antonopoulos DA,
Sogin ML, Morrison HG, Raffals L, Chang EB, Huffnagle
GB, Schmidt TM, Cole JR & Tiedje JM (2013). A
gene-targeted approach to investigate the intestinal
butyrate-producing bacterial community.Microbiome 1, 8.
Vogt JA, Ishii-Schrade KB, Pencharz PB &Wolever TM (2004).
L-Rhamnose increases serum propionate after long-term
supplementation, but lactulose does not raise serum acetate.
Am J Clin Nutr 80, 1254–1261.
Wang DC, Sun CH, Liu LY, Sun XH, Jin XW, Song WL,
Liu XQ &Wan XL (2012). Serum fatty acid profiles using
GC-MS and multivariate statistical analysis: potential
biomarkers of Alzheimer’s disease. Neurobiol Aging 33,
1057–1066.
Wiltrout DW & Satter LD (1972). Contribution of propionate
to glucose synthesis in the lactating and nonlactating cow.
J Dairy Sci 55, 307–317.
Wolever TM, Spadafora PJ, Cunnane SC, et al. (1995).
Propionate inhibits incorporation of colonic
[1,2-13C]acetate into plasma lipids in humans. Am J Clin
Nutr 61, 1241–1247.
Wolfe RR & Jahoor F (1990). Recovery of labeled CO2 during
the infusion of C-1- vs C-2-labeled acetate: implications for
tracer studies of substrate oxidation. Am J Clin Nutr 51,
248–252.
Zhao G, Liu JF, Nyman M & Jonsson JA (2007). Determination
of short-chain fatty acids in serum by hollow fiber supported
liquid membrane extraction coupled with gas
chromatography. J Chromatogr B Analyt Technol Biomed Life
Sci 846, 202–208.
Additional information
Competing interests
The authors declare that they have no competing interests.
Author contributions
The work was performed at the Translational Research Center
for Gastrointestinal Disorders (Laboratory of Digestion and
C© 2016 The Authors. The Journal of Physiology C© 2016 The Physiological Society
J Physiol 595.2 Short-chain fatty acid systemic availability and metabolism in humans 555
Absorption) of the KU Leuven, Leuven, Belgium. EB, HH and
KAV were responsible for the study concept and design. EB, LD,
HH and KV executed the intervention study and acquired the
data. EB, SVG,LD,KV,TP,VD,GV,LDV,CMC,PA, JADandKAV
were responsible for data analysis and interpretation. TP, KV,GV
and PA provided technical and material support. EB, SVG, LD,
TP, KV,VDP,HH,GVM, LDV,CMC, PA, JD,KAVcontributed to
the writing and critically revision of the manuscript. All authors
approved the final version of the manuscript. All authors agree
to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the
work are appropriately investigated and resolved. All persons
designated as authors qualify for authorship, and all those who
qualify for authorship are listed.
Funding
The work was conducted in the framework of the W. K. Kellogg
Chair in Cereal Science and Nutrition at the KU Leuven (chair
holders J. A. Delcour and K. Verbeke) andwas further supported
by the Fund for Scientific Research-Flanders (FWOVlaanderen,
Belgium; grants FWO-G.0109.07 and FWO-1.5.131.10).
Acknowledgements
Fruitful discussions with Drs C. M. Courtin (KU Leuven), L.
Sanders, K. Spence, J. Reid, A. Birkett, N. Almeida and R.
McDermott (Kellogg Company, Battle Creek, MI, USA) are
highly appreciated.
C© 2016 The Authors. The Journal of Physiology C© 2016 The Physiological Society
